“…This gap in efficacy has motivated new research aimed at identifying alternative intervention approaches that may enhance clinical outcomes. One potentially promising avenue has identified dysfunction in the mesolimbic dopamine (DA) system, which has been linked to observations of motivational deficits in SAD, and consistent with a social anhedonic phenotype, which has been linked as a correlate of SAD (Tiihonen et al, 1997;Schneier et al, 2000Schneier et al, , 2008Cremers et al, 2015;Richey et al, 2013Richey et al, , 2017Richey et al, , 2019; but see also Schneier et al, 2009), but not other anxiety disorders such as generalized anxiety disorder (Brown et al, 1998). Dysfunction in the ventral striatum (VS) is central to this model, with a number of studies demonstrating reduced activity in the VS in relation to social but not non-social incentives (Richey et al, 2013(Richey et al, , 2017Maresh et al, 2014).…”